Sandra A. Banta-Wright, MN, RNC, NNP; Robert D. Steiner, MD Neonates with profound and prolonged hyperammonemia with coma due to urea cycle defect will have had a neurological insult to the brain ...

Zevra Therapeutics Inc (ZVRA) reports significant progress with Myle's launch and strategic planning, despite financial ...

William Blair analyst Sami Corwin has maintained their bullish stance on ZVRA stock, giving a Buy rating today. Sami Corwin’s rating is ...

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...

Leerink initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $17 price target The firm believes CMP-CPS-001, the lead ...

Researchers will aim to target developing therapies for urea cycle disorders, which affect approximately one in every 35,000 children, according to the Penn Medicine announcement. Central to the ...

FDA approval of MIPLYFFA™ and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra received rare pediatric disease Priority Review Voucher Company ...

Let's turn to OLPRUVA, our commercial product for the treatment of certain urea cycle disorders or UCDs. Our launch has been impacted by low patient awareness and reimbursement hurdles for new ...

Solutions mean success to Win Biologics as entrepreneur Carolyn Wingate talks about her investment in soil health, Tim Unruh ...

Nutrien sits on the higher end of the phosphate fertilizer cost curve, though this is by far its smallest business. Although it is a fully integrated phosphate producer, its cash costs of production ...

( MENAFN - IANS) Chandigarh, Nov 5 (IANS) Haryana Agriculture Minister Shyam Singh Rana on Tuesday said the government is ...